Clinical Trials

GastrointestinalGynecologic

442 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

NCT04840589 2026-03-18

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

66 enrolled

Neoplasm Metastasis, Ovarian Neoplasms

NCT05198804 2026-03-18

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

117 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05554328 2026-03-18

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05554367 2026-03-18

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

199 enrolled

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

DermatologicGenitourinaryGynecologicHead & NeckThoracic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT06412510 2026-03-18

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

22 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06995898 2026-03-18

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07424547 2026-03-18

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

BreastGenitourinaryGynecologicThoracic

386 enrolled

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT07480785 2026-03-18

TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

Phase NA Recruiting

780 enrolled

Leiomyoma, Ovarian Neoplasms, Postoperative Nausea and Vomiting, Gallstones

NCT07480954 2026-03-18

DUAL-OV-CAR-NK

36 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06276491 2026-03-17

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

282 enrolled

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms

NCT06926075 2026-03-17

ADVICE

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicThoracic

80 enrolled

Breast Neoplasms, Glioblastoma, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms

NCT06969833 2026-03-17

BCB-OVAIRE

Phase NA Recruiting

371 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06973161 2026-03-17

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

Recruiting

105 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06993844 2026-03-17

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

BreastGynecologicHead & Neck

233 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

134 enrolled

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Active not recruiting

224 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03842982 2026-03-16

CHIPPI

362 enrolled

Ovarian Neoplasms

NCT04389632 2026-03-16

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Phase 2 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05479045 2026-03-16

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

24 enrolled

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06003231 2026-03-16

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

120 enrolled

GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06412120 2026-03-16

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Ovarian Neoplasms

NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

12 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07214779 2026-03-16

MAESTRA 2

Phase 3 Recruiting

466 enrolled

Phase NA Not yet recruiting

Ovarian Neoplasms

NCT07455071 2026-03-16

YS247

9 enrolled

Ovarian Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

120 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01247779 2026-03-13

ROBO-GYN

Phase NA Completed

386 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT01950572 2026-03-13

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Recruiting

1,000 enrolled

Biliary Tract Neoplasms, Lung Neoplasms, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

770 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07186842 2026-03-13

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9